Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial) View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-03-28

AUTHORS

Maria Patrizia Carrieri, Camelia Protopopescu, Zobair Younossi, Antoine Vilotitch, Hélène Fontaine, Ventzislava Petrov-Sanchez, Fabienne Marcellin, Fabrice Carrat, Christophe Hézode, Marc Bourlière

ABSTRACT

ObjectiveWe aimed to compare health-related quality of life (HRQL) during and after hepatitis C virus (HCV) treatment in patients receiving pegylated-interferon (PEG-IFN)-containing therapy (including boceprevir or telaprevir—ANRS CO20 CUPIC cohort) who subsequently switched to PEG-IFN-free regimens (sofosbuvir + ledipasvir with or without ribavirin [RBV]—SIRIUS trial).MethodsTwo analyses were performed. The first compared physical (PCS) and mental (MCS) HRQL (MOS SF-12) scores during treatment between CUPIC and SIRIUS. The second compared PCS and MCS scores after treatment end between CUPIC and SIRIUS. The analyses used linear regression mixed models adjusted for pre-treatment HRQL scores, gender, and age at each visit.ResultsAmong patients enrolled successively in both studies, 43 (corresponding to 212 HRQL assessments) and 43 (82 HRQL assessments) were eligible for the ‘during’ and ‘post’ treatment analyses, respectively. In the ‘during-treatment’ analysis, we found significantly higher PCS and MCS values during PEG-IFN-free treatment than for PEG-IFN-containing treatment. In the ‘post-treatment’ analysis, results showed significantly higher MCS values after PEG-IFN-free treatment than after PEG-IFN-containing treatment. No significant difference was found for PCS in the post-treatment analysis.ConclusionsThese results highlight an improvement in both physical and mental HRQL during HCV treatment, but no major improvement in physical HRQL after treatment end, when comparing PEG-IFN-free regimens with PEG-IFN-containing regimens. This suggests that in the PEG-IFN-free regimens era, screening and comprehensive care of comorbidities and residual somatic symptoms during treatment, and especially after HCV clearance, are still needed to improve patient outcomes. More... »

PAGES

605-614

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40271-017-0232-1

DOI

http://dx.doi.org/10.1007/s40271-017-0232-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1084038585

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28353221


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Age Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiviral Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzimidazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Comorbidity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorenes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Health Status", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepatitis C, Chronic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mental Health", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oligopeptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Reported Outcome Measures", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Polyethylene Glycols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proline", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sex Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sofosbuvir", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sustained Virologic Response", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Uridine Monophosphate", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "ORS PACA (Observatoire R\u00e9gional de la Sant\u00e9 Provence-Alpes-C\u00f4te d\u2019Azur), Marseille, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Facult\u00e9 de M\u00e9decine, Aix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Sant\u00e9 & Traitement de l\u2019Information M\u00e9dicale, 27 Bd. Jean Moulin, 13385, Marseille Cedex 5, France", 
            "ORS PACA (Observatoire R\u00e9gional de la Sant\u00e9 Provence-Alpes-C\u00f4te d\u2019Azur), Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carrieri", 
        "givenName": "Maria Patrizia", 
        "id": "sg:person.01324330327.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324330327.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "ORS PACA (Observatoire R\u00e9gional de la Sant\u00e9 Provence-Alpes-C\u00f4te d\u2019Azur), Marseille, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Facult\u00e9 de M\u00e9decine, Aix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Sant\u00e9 & Traitement de l\u2019Information M\u00e9dicale, 27 Bd. Jean Moulin, 13385, Marseille Cedex 5, France", 
            "ORS PACA (Observatoire R\u00e9gional de la Sant\u00e9 Provence-Alpes-C\u00f4te d\u2019Azur), Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Protopopescu", 
        "givenName": "Camelia", 
        "id": "sg:person.01123072724.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123072724.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, 22039, Annandale, VA, USA", 
          "id": "http://www.grid.ac/institutes/grid.417781.c", 
          "name": [
            "Department of Medicine, Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, 22039, Annandale, VA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Younossi", 
        "givenName": "Zobair", 
        "id": "sg:person.01245263262.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245263262.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "ORS PACA (Observatoire R\u00e9gional de la Sant\u00e9 Provence-Alpes-C\u00f4te d\u2019Azur), Marseille, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Facult\u00e9 de M\u00e9decine, Aix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Sant\u00e9 & Traitement de l\u2019Information M\u00e9dicale, 27 Bd. Jean Moulin, 13385, Marseille Cedex 5, France", 
            "ORS PACA (Observatoire R\u00e9gional de la Sant\u00e9 Provence-Alpes-C\u00f4te d\u2019Azur), Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vilotitch", 
        "givenName": "Antoine", 
        "id": "sg:person.01263436002.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01263436002.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hepatology Unit, Groupe hospitalier Cochin-H\u00f4tel Dieu, AP-HP, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.50550.35", 
          "name": [
            "INSERM, U1016, H\u00f4pital Cochin, 27 rue du Faubourg Saint Jacques, 75014, Paris, France", 
            "Hepatology Unit, Groupe hospitalier Cochin-H\u00f4tel Dieu, AP-HP, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fontaine", 
        "givenName": "H\u00e9l\u00e8ne", 
        "id": "sg:person.0673006267.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673006267.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Unit for Basic and Clinical Research on Viral Hepatitis, ANRS (France Recherche Nord and Sud Sida-HIV H\u00e9patites FRENSH), Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.453032.3", 
          "name": [
            "Unit for Basic and Clinical Research on Viral Hepatitis, ANRS (France Recherche Nord and Sud Sida-HIV H\u00e9patites FRENSH), Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Petrov-Sanchez", 
        "givenName": "Ventzislava", 
        "id": "sg:person.0733743621.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733743621.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "ORS PACA (Observatoire R\u00e9gional de la Sant\u00e9 Provence-Alpes-C\u00f4te d\u2019Azur), Marseille, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Facult\u00e9 de M\u00e9decine, Aix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Sant\u00e9 & Traitement de l\u2019Information M\u00e9dicale, 27 Bd. Jean Moulin, 13385, Marseille Cedex 5, France", 
            "ORS PACA (Observatoire R\u00e9gional de la Sant\u00e9 Provence-Alpes-C\u00f4te d\u2019Azur), Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marcellin", 
        "givenName": "Fabienne", 
        "id": "sg:person.0671423404.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671423404.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Public Health Unit, H\u00f4pital Saint-Antoine, AP-HP, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.412370.3", 
          "name": [
            "Sorbonne Universities, UPMC University of Paris 06, INSERM, Pierre Louis Institute of Epidemiology and Public Health (IPLESP UMRS 1136), Paris, France", 
            "Public Health Unit, H\u00f4pital Saint-Antoine, AP-HP, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carrat", 
        "givenName": "Fabrice", 
        "id": "sg:person.0725234060.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0725234060.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hepatology and Gastroenterology, H\u00f4pital Henri Mondor, AP-HP, University of Paris-Est, INSERM, U955, Cr\u00e9teil, France", 
          "id": "http://www.grid.ac/institutes/grid.412116.1", 
          "name": [
            "Department of Hepatology and Gastroenterology, H\u00f4pital Henri Mondor, AP-HP, University of Paris-Est, INSERM, U955, Cr\u00e9teil, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "H\u00e9zode", 
        "givenName": "Christophe", 
        "id": "sg:person.0645546730.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645546730.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hepato-Gastroenterology, H\u00f4pital Saint Joseph, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.414364.0", 
          "name": [
            "Department of Hepato-Gastroenterology, H\u00f4pital Saint Joseph, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bourli\u00e8re", 
        "givenName": "Marc", 
        "id": "sg:person.01355441765.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355441765.00"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1023/a:1012588218728", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051815426", 
          "https://doi.org/10.1023/a:1012588218728"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-230x-13-16", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048602699", 
          "https://doi.org/10.1186/1471-230x-13-16"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-03-28", 
    "datePublishedReg": "2017-03-28", 
    "description": "ObjectiveWe aimed to compare health-related quality of life (HRQL) during and after hepatitis C virus (HCV) treatment in patients receiving pegylated-interferon (PEG-IFN)-containing therapy (including boceprevir or telaprevir\u2014ANRS CO20 CUPIC cohort) who subsequently switched to PEG-IFN-free regimens (sofosbuvir\u00a0+\u00a0ledipasvir with or without ribavirin [RBV]\u2014SIRIUS trial).MethodsTwo analyses were performed. The first compared physical (PCS) and mental (MCS) HRQL (MOS SF-12) scores during treatment between CUPIC and SIRIUS. The second compared PCS and MCS scores after treatment end between CUPIC and SIRIUS. The analyses used linear regression mixed models adjusted for pre-treatment HRQL scores, gender, and age at each visit.ResultsAmong patients enrolled successively in both studies, 43 (corresponding to 212 HRQL assessments) and 43 (82 HRQL assessments) were eligible for the \u2018during\u2019 and \u2018post\u2019 treatment analyses, respectively. In the \u2018during-treatment\u2019 analysis, we found significantly higher PCS and MCS values during PEG-IFN-free treatment than for PEG-IFN-containing treatment. In the \u2018post-treatment\u2019 analysis, results showed significantly higher MCS values after PEG-IFN-free treatment than after PEG-IFN-containing treatment. No significant difference was found for PCS in the post-treatment analysis.ConclusionsThese results highlight an improvement in both physical and mental HRQL during HCV treatment, but no major improvement in physical HRQL after treatment end, when comparing PEG-IFN-free regimens with PEG-IFN-containing regimens. This suggests that in the PEG-IFN-free regimens era, screening and comprehensive care of comorbidities and residual somatic symptoms during treatment, and especially after HCV clearance, are still needed to improve patient outcomes.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40271-017-0232-1", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1038760", 
        "issn": [
          "1178-1653", 
          "1178-1661"
        ], 
        "name": "The Patient - Patient-Centered Outcomes Research", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "10"
      }
    ], 
    "keywords": [
      "PEG-IFN", 
      "free regimens", 
      "HRQL scores", 
      "treatment end", 
      "hepatitis C virus (HCV) treatment", 
      "residual somatic symptoms", 
      "interferon-free regimens", 
      "health-related quality", 
      "C virus treatment", 
      "free treatment", 
      "quality of life", 
      "MCS values", 
      "ResultsAmong patients", 
      "HCV treatment", 
      "physical HRQL", 
      "HCV clearance", 
      "chronic HCV", 
      "mental HRQL", 
      "MCS scores", 
      "patient outcomes", 
      "comprehensive care", 
      "virus treatment", 
      "regimens", 
      "post-treatment analysis", 
      "somatic symptoms", 
      "higher PCS", 
      "patients", 
      "ConclusionsThese results", 
      "treatment analysis", 
      "HRQL", 
      "treatment", 
      "significant differences", 
      "scores", 
      "linear regression", 
      "comorbidities", 
      "HCV", 
      "PCS", 
      "therapy", 
      "symptoms", 
      "ObjectiveWe", 
      "visits", 
      "clearance", 
      "care", 
      "age", 
      "outcomes", 
      "life", 
      "health", 
      "screening", 
      "major improvements", 
      "gender", 
      "improvement", 
      "regression", 
      "analysis", 
      "differences", 
      "quality", 
      "study", 
      "end", 
      "results", 
      "Sirius", 
      "values", 
      "Physical", 
      "era", 
      "PEG", 
      "model"
    ], 
    "name": "Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial)", 
    "pagination": "605-614", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1084038585"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40271-017-0232-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28353221"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40271-017-0232-1", 
      "https://app.dimensions.ai/details/publication/pub.1084038585"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_734.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40271-017-0232-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40271-017-0232-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40271-017-0232-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40271-017-0232-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40271-017-0232-1'


 

This table displays all metadata directly associated to this object as RDF triples.

317 TRIPLES      21 PREDICATES      116 URIs      106 LITERALS      32 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40271-017-0232-1 schema:about N0764f12d8bc749d0b6d9f044ec8bcb9e
2 N08dddc9b2e7640c1a801b9008938fa97
3 N09065cc5ec3e40fda0205d34e3b47cfd
4 N1c91f6d325a7431890fb178fe821a3cb
5 N2745952fac87451ebc9c4f3206660249
6 N2edb4c94ea3441bb8640cdb59c2ccb8a
7 N33e9b6f671b643198ea732468c89eb1f
8 N34c945059210403d93732f2826bef001
9 N3583e7a50e1b41cfb0741c7103d1c124
10 N3eb09f3f97b64f4ba61067b3e00b405e
11 N40ba17840ffc49c581de2618078fcfbe
12 N41cb6cb7c5264ecf96f64f4ee78e9767
13 N50d73b3bfd464eb0976c07100ad33144
14 N5ec4ba6cc05c4eaa943ecf7ce818e390
15 N625547ed29814c9994197505854279e4
16 N6a265f31709d454b923f9c0984ecf338
17 N70bd3c585db14c7db64d3bfaac588cf6
18 N8773bf7fe98643ac9791ab1aab215637
19 N8a5241e6d30f4dbf9a951c1ad004131f
20 N9d1a8f4aa7aa4f998f5e0b72e497dad5
21 Na35e627f8df2421e85efb5d88d3af38c
22 Naea63b22c9a9412e9478060c24f79170
23 Nb23ef7e74c794198bfe79bd63127e3db
24 Nbfe44eabeaa849d081d9c24dd8288a11
25 Ne8136d2b19c94ffaa0029b68e1b1f5e0
26 anzsrc-for:11
27 anzsrc-for:1117
28 schema:author N1ccf123c1f2840f7aac937222d8d0b6c
29 schema:citation sg:pub.10.1023/a:1012588218728
30 sg:pub.10.1186/1471-230x-13-16
31 schema:datePublished 2017-03-28
32 schema:datePublishedReg 2017-03-28
33 schema:description ObjectiveWe aimed to compare health-related quality of life (HRQL) during and after hepatitis C virus (HCV) treatment in patients receiving pegylated-interferon (PEG-IFN)-containing therapy (including boceprevir or telaprevir—ANRS CO20 CUPIC cohort) who subsequently switched to PEG-IFN-free regimens (sofosbuvir + ledipasvir with or without ribavirin [RBV]—SIRIUS trial).MethodsTwo analyses were performed. The first compared physical (PCS) and mental (MCS) HRQL (MOS SF-12) scores during treatment between CUPIC and SIRIUS. The second compared PCS and MCS scores after treatment end between CUPIC and SIRIUS. The analyses used linear regression mixed models adjusted for pre-treatment HRQL scores, gender, and age at each visit.ResultsAmong patients enrolled successively in both studies, 43 (corresponding to 212 HRQL assessments) and 43 (82 HRQL assessments) were eligible for the ‘during’ and ‘post’ treatment analyses, respectively. In the ‘during-treatment’ analysis, we found significantly higher PCS and MCS values during PEG-IFN-free treatment than for PEG-IFN-containing treatment. In the ‘post-treatment’ analysis, results showed significantly higher MCS values after PEG-IFN-free treatment than after PEG-IFN-containing treatment. No significant difference was found for PCS in the post-treatment analysis.ConclusionsThese results highlight an improvement in both physical and mental HRQL during HCV treatment, but no major improvement in physical HRQL after treatment end, when comparing PEG-IFN-free regimens with PEG-IFN-containing regimens. This suggests that in the PEG-IFN-free regimens era, screening and comprehensive care of comorbidities and residual somatic symptoms during treatment, and especially after HCV clearance, are still needed to improve patient outcomes.
34 schema:genre article
35 schema:isAccessibleForFree false
36 schema:isPartOf N1f71fa6d2c33401981f4687b120de0ea
37 N6470f73da8d84808933fbda73b59a19d
38 sg:journal.1038760
39 schema:keywords C virus treatment
40 ConclusionsThese results
41 HCV
42 HCV clearance
43 HCV treatment
44 HRQL
45 HRQL scores
46 MCS scores
47 MCS values
48 ObjectiveWe
49 PCS
50 PEG
51 PEG-IFN
52 Physical
53 ResultsAmong patients
54 Sirius
55 age
56 analysis
57 care
58 chronic HCV
59 clearance
60 comorbidities
61 comprehensive care
62 differences
63 end
64 era
65 free regimens
66 free treatment
67 gender
68 health
69 health-related quality
70 hepatitis C virus (HCV) treatment
71 higher PCS
72 improvement
73 interferon-free regimens
74 life
75 linear regression
76 major improvements
77 mental HRQL
78 model
79 outcomes
80 patient outcomes
81 patients
82 physical HRQL
83 post-treatment analysis
84 quality
85 quality of life
86 regimens
87 regression
88 residual somatic symptoms
89 results
90 scores
91 screening
92 significant differences
93 somatic symptoms
94 study
95 symptoms
96 therapy
97 treatment
98 treatment analysis
99 treatment end
100 values
101 virus treatment
102 visits
103 schema:name Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial)
104 schema:pagination 605-614
105 schema:productId N07acfcad952845c0a8acb6e4cb5aa48c
106 Nb2355340bb414b5789450ecafcdcf6a5
107 Necf3913ee26748768a8b3127d32ad621
108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084038585
109 https://doi.org/10.1007/s40271-017-0232-1
110 schema:sdDatePublished 2022-12-01T06:36
111 schema:sdLicense https://scigraph.springernature.com/explorer/license/
112 schema:sdPublisher N031915ac75a5467da35c6014ba5b3909
113 schema:url https://doi.org/10.1007/s40271-017-0232-1
114 sgo:license sg:explorer/license/
115 sgo:sdDataset articles
116 rdf:type schema:ScholarlyArticle
117 N031915ac75a5467da35c6014ba5b3909 schema:name Springer Nature - SN SciGraph project
118 rdf:type schema:Organization
119 N0764f12d8bc749d0b6d9f044ec8bcb9e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Oligopeptides
121 rdf:type schema:DefinedTerm
122 N07acfcad952845c0a8acb6e4cb5aa48c schema:name dimensions_id
123 schema:value pub.1084038585
124 rdf:type schema:PropertyValue
125 N08dddc9b2e7640c1a801b9008938fa97 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Age Factors
127 rdf:type schema:DefinedTerm
128 N09065cc5ec3e40fda0205d34e3b47cfd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Fluorenes
130 rdf:type schema:DefinedTerm
131 N1c91f6d325a7431890fb178fe821a3cb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Antiviral Agents
133 rdf:type schema:DefinedTerm
134 N1ccf123c1f2840f7aac937222d8d0b6c rdf:first sg:person.01324330327.99
135 rdf:rest N29bac76dfffc46a885850554baf0d948
136 N1f71fa6d2c33401981f4687b120de0ea schema:issueNumber 5
137 rdf:type schema:PublicationIssue
138 N2745952fac87451ebc9c4f3206660249 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Health Status
140 rdf:type schema:DefinedTerm
141 N29bac76dfffc46a885850554baf0d948 rdf:first sg:person.01123072724.28
142 rdf:rest Nc5bdb90d7dba48b68ec454e9057fc5eb
143 N2edb4c94ea3441bb8640cdb59c2ccb8a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Patient Reported Outcome Measures
145 rdf:type schema:DefinedTerm
146 N33e9b6f671b643198ea732468c89eb1f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Sofosbuvir
148 rdf:type schema:DefinedTerm
149 N34c945059210403d93732f2826bef001 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Double-Blind Method
151 rdf:type schema:DefinedTerm
152 N3583e7a50e1b41cfb0741c7103d1c124 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Polyethylene Glycols
154 rdf:type schema:DefinedTerm
155 N3c10a32932244cd3ae02ca36a9736781 rdf:first sg:person.0645546730.39
156 rdf:rest Na156b77ea8de4c7fbdf323700cfd94d6
157 N3eb09f3f97b64f4ba61067b3e00b405e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Proline
159 rdf:type schema:DefinedTerm
160 N40ba17840ffc49c581de2618078fcfbe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Benzimidazoles
162 rdf:type schema:DefinedTerm
163 N41cb6cb7c5264ecf96f64f4ee78e9767 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Cohort Studies
165 rdf:type schema:DefinedTerm
166 N4a9f36e6dc9547c4af85ef8cc8a1a3e7 rdf:first sg:person.0725234060.17
167 rdf:rest N3c10a32932244cd3ae02ca36a9736781
168 N50d73b3bfd464eb0976c07100ad33144 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Male
170 rdf:type schema:DefinedTerm
171 N5ec4ba6cc05c4eaa943ecf7ce818e390 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Quality of Life
173 rdf:type schema:DefinedTerm
174 N625547ed29814c9994197505854279e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Severity of Illness Index
176 rdf:type schema:DefinedTerm
177 N6470f73da8d84808933fbda73b59a19d schema:volumeNumber 10
178 rdf:type schema:PublicationVolume
179 N6a265f31709d454b923f9c0984ecf338 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Sustained Virologic Response
181 rdf:type schema:DefinedTerm
182 N70bd3c585db14c7db64d3bfaac588cf6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Mental Health
184 rdf:type schema:DefinedTerm
185 N8773bf7fe98643ac9791ab1aab215637 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Middle Aged
187 rdf:type schema:DefinedTerm
188 N8a5241e6d30f4dbf9a951c1ad004131f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Comorbidity
190 rdf:type schema:DefinedTerm
191 N9d1a8f4aa7aa4f998f5e0b72e497dad5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Sex Factors
193 rdf:type schema:DefinedTerm
194 Na156b77ea8de4c7fbdf323700cfd94d6 rdf:first sg:person.01355441765.00
195 rdf:rest rdf:nil
196 Na35e627f8df2421e85efb5d88d3af38c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Humans
198 rdf:type schema:DefinedTerm
199 Naea63b22c9a9412e9478060c24f79170 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Hepatitis C, Chronic
201 rdf:type schema:DefinedTerm
202 Nb2355340bb414b5789450ecafcdcf6a5 schema:name doi
203 schema:value 10.1007/s40271-017-0232-1
204 rdf:type schema:PropertyValue
205 Nb23ef7e74c794198bfe79bd63127e3db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Uridine Monophosphate
207 rdf:type schema:DefinedTerm
208 Nbfe44eabeaa849d081d9c24dd8288a11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
209 schema:name Female
210 rdf:type schema:DefinedTerm
211 Nc5bdb90d7dba48b68ec454e9057fc5eb rdf:first sg:person.01245263262.85
212 rdf:rest Nf6fb97ce893a41cbace4ecd9dfc872b1
213 Nd7bd537ed33d4b349752dcd5346b45fb rdf:first sg:person.0673006267.89
214 rdf:rest Nda6b04ea0e1243d7b15d057427d13719
215 Nda6b04ea0e1243d7b15d057427d13719 rdf:first sg:person.0733743621.15
216 rdf:rest Nff3c1a64b4c047678a98eff48921f581
217 Ne8136d2b19c94ffaa0029b68e1b1f5e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
218 schema:name Aged
219 rdf:type schema:DefinedTerm
220 Necf3913ee26748768a8b3127d32ad621 schema:name pubmed_id
221 schema:value 28353221
222 rdf:type schema:PropertyValue
223 Nf6fb97ce893a41cbace4ecd9dfc872b1 rdf:first sg:person.01263436002.67
224 rdf:rest Nd7bd537ed33d4b349752dcd5346b45fb
225 Nff3c1a64b4c047678a98eff48921f581 rdf:first sg:person.0671423404.46
226 rdf:rest N4a9f36e6dc9547c4af85ef8cc8a1a3e7
227 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
228 schema:name Medical and Health Sciences
229 rdf:type schema:DefinedTerm
230 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
231 schema:name Public Health and Health Services
232 rdf:type schema:DefinedTerm
233 sg:journal.1038760 schema:issn 1178-1653
234 1178-1661
235 schema:name The Patient - Patient-Centered Outcomes Research
236 schema:publisher Springer Nature
237 rdf:type schema:Periodical
238 sg:person.01123072724.28 schema:affiliation grid-institutes:None
239 schema:familyName Protopopescu
240 schema:givenName Camelia
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123072724.28
242 rdf:type schema:Person
243 sg:person.01245263262.85 schema:affiliation grid-institutes:grid.417781.c
244 schema:familyName Younossi
245 schema:givenName Zobair
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245263262.85
247 rdf:type schema:Person
248 sg:person.01263436002.67 schema:affiliation grid-institutes:None
249 schema:familyName Vilotitch
250 schema:givenName Antoine
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01263436002.67
252 rdf:type schema:Person
253 sg:person.01324330327.99 schema:affiliation grid-institutes:None
254 schema:familyName Carrieri
255 schema:givenName Maria Patrizia
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324330327.99
257 rdf:type schema:Person
258 sg:person.01355441765.00 schema:affiliation grid-institutes:grid.414364.0
259 schema:familyName Bourlière
260 schema:givenName Marc
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355441765.00
262 rdf:type schema:Person
263 sg:person.0645546730.39 schema:affiliation grid-institutes:grid.412116.1
264 schema:familyName Hézode
265 schema:givenName Christophe
266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645546730.39
267 rdf:type schema:Person
268 sg:person.0671423404.46 schema:affiliation grid-institutes:None
269 schema:familyName Marcellin
270 schema:givenName Fabienne
271 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671423404.46
272 rdf:type schema:Person
273 sg:person.0673006267.89 schema:affiliation grid-institutes:grid.50550.35
274 schema:familyName Fontaine
275 schema:givenName Hélène
276 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673006267.89
277 rdf:type schema:Person
278 sg:person.0725234060.17 schema:affiliation grid-institutes:grid.412370.3
279 schema:familyName Carrat
280 schema:givenName Fabrice
281 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0725234060.17
282 rdf:type schema:Person
283 sg:person.0733743621.15 schema:affiliation grid-institutes:grid.453032.3
284 schema:familyName Petrov-Sanchez
285 schema:givenName Ventzislava
286 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733743621.15
287 rdf:type schema:Person
288 sg:pub.10.1023/a:1012588218728 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051815426
289 https://doi.org/10.1023/a:1012588218728
290 rdf:type schema:CreativeWork
291 sg:pub.10.1186/1471-230x-13-16 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048602699
292 https://doi.org/10.1186/1471-230x-13-16
293 rdf:type schema:CreativeWork
294 grid-institutes:None schema:alternateName ORS PACA (Observatoire Régional de la Santé Provence-Alpes-Côte d’Azur), Marseille, France
295 schema:name Faculté de Médecine, Aix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l’Information Médicale, 27 Bd. Jean Moulin, 13385, Marseille Cedex 5, France
296 ORS PACA (Observatoire Régional de la Santé Provence-Alpes-Côte d’Azur), Marseille, France
297 rdf:type schema:Organization
298 grid-institutes:grid.412116.1 schema:alternateName Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, AP-HP, University of Paris-Est, INSERM, U955, Créteil, France
299 schema:name Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, AP-HP, University of Paris-Est, INSERM, U955, Créteil, France
300 rdf:type schema:Organization
301 grid-institutes:grid.412370.3 schema:alternateName Public Health Unit, Hôpital Saint-Antoine, AP-HP, Paris, France
302 schema:name Public Health Unit, Hôpital Saint-Antoine, AP-HP, Paris, France
303 Sorbonne Universities, UPMC University of Paris 06, INSERM, Pierre Louis Institute of Epidemiology and Public Health (IPLESP UMRS 1136), Paris, France
304 rdf:type schema:Organization
305 grid-institutes:grid.414364.0 schema:alternateName Department of Hepato-Gastroenterology, Hôpital Saint Joseph, Marseille, France
306 schema:name Department of Hepato-Gastroenterology, Hôpital Saint Joseph, Marseille, France
307 rdf:type schema:Organization
308 grid-institutes:grid.417781.c schema:alternateName Department of Medicine, Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, 22039, Annandale, VA, USA
309 schema:name Department of Medicine, Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, 22039, Annandale, VA, USA
310 rdf:type schema:Organization
311 grid-institutes:grid.453032.3 schema:alternateName Unit for Basic and Clinical Research on Viral Hepatitis, ANRS (France Recherche Nord and Sud Sida-HIV Hépatites FRENSH), Paris, France
312 schema:name Unit for Basic and Clinical Research on Viral Hepatitis, ANRS (France Recherche Nord and Sud Sida-HIV Hépatites FRENSH), Paris, France
313 rdf:type schema:Organization
314 grid-institutes:grid.50550.35 schema:alternateName Hepatology Unit, Groupe hospitalier Cochin-Hôtel Dieu, AP-HP, Paris, France
315 schema:name Hepatology Unit, Groupe hospitalier Cochin-Hôtel Dieu, AP-HP, Paris, France
316 INSERM, U1016, Hôpital Cochin, 27 rue du Faubourg Saint Jacques, 75014, Paris, France
317 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...